| 영문 | ovulation | 한글 | 배란 |
|---|---|---|---|
| 설명 | 난소에 존재하는 난포가 성숙하여 터지면서 난자를 배출하는 과정을 배란이라 한다. 이러한 배란은 앞으로 들어올 정자에 대한 수정준비과정으로 남자의 정자가 접근하여 난자와의 만남을 쉽게 한다. 배란이 일어난 후 난포는 황체로 변하게 되며, 이후 황체에서 황체호르몬이 분비되어 수정되지 않은 상태에서는 월경이 일어난다. |
||
| 영문 | ovulation induction | 한글 | 배란유도 |
|---|---|---|---|
| 설명 | 인공배란유도 기법으로 배란이 되도록 인위적으로 유도하는 것. |
||
| 영문 | ovulation cycle | 한글 | 배란주기 |
|---|---|---|---|
| 설명 | 사춘기가 되어 난소가 뇌하수체전엽으로부터의 생식샘자극호르몬의 작용을 받아 원시난포가 발육하고 성숙난포가 된다. 결국에는 난포벽이 파열되어 과립막세포로 둘러싸인 난자가 복강내로 배출된다(배란). 배란 후 24~96시간으로 과립막세포가 비대증식해서 황체를 형성한다. 수정되지 않은 경우 월경황체는 약 10일간 존속하고 퇴행변성해서 백체가 된다. 황체가 퇴행변성하면 다음의 난포가 성숙한다. 난소에서는 이 주기가 반복되고 있다. |
||
| HCG, hCG | Human Chorionic Gonadotropin; 사람융모성성선자극호르몬 1. Placental Glycoprotein Hormone &nbs... |
|---|---|
| BPTI | basic pancreatic trypsin inhibitor; basic polyvalent trypsin inhibitor; bovine pancreatic trypsin in... |
| PI | first meiotic prophase; isoelectric point; pacing impulse; package insert; pancreatic insufficiency;... |
| ETO | estimated time of ovulation |
| OIH | Office of International Health; orthoiodohippurate; ovulation-inducing hormone |
| OR | Ovulation rate |
|---|---|
| ACE inhibitor | angiotensin converting enzyme inhibitor |
| CPI | 1-cysteine proteinase inhibitor |
| PIC | 1-plasmin inhibitor complex |
| PAI-1 | Plaminogen Activator Inhibitor-1 |
oligo- 괴소, 결핍 등의 뜻을 나타내는 접두어.
oligo-ovulation
| ovulation inhibitor | A compound that inhibits ovulation; often found in oral contraceptives. (05 Mar 2000) |
|---|
| ovulation | <gynaecology> The discharge of a secondary oocyte from a vesicular follicle of the ovary. (18 Nov 1997) |
|---|---|
| ovulation detection | Methods for recognition of the occurrence of ovulation. (12 Dec 1998) |
| ovulation induction | Techniques for the artifical induction of ovulation. (12 Dec 1998) |
| law of constant numbers in ovulation | The number of ova discharged at each ovulation is nearly constant for any given species. (05 Mar 2000) |
| a1-trypsin inhibitor | A glycoprotein that is the major protease inhibitor of human serum, is synthesised in the liver, and is genetically polymorphic due to the presence of over 20 alleles; individuals appropriately homozygous are deficient in a1-trypsin and are predisposed to pulmonary emphysema and juvenile hepatic cirrhosis because of alterations in the amino acid and sialic acid components of the glycoprotein. A1-Antitrypsin also inhibits thrombin. Synonym: a1-trypsin inhibitor, human a1-proteinase inhibitor. (05 Mar 2000) |
| ACE inhibitor | <pharmacology> A group of antihypertensive medications that work by inhibiting an enzyme (angiotensin-converting enzyme) that is important in the regulation of blood pressure. Studies have also indicated that it may help prevent or slow the progression of kidney disease in patients with diabetes. Examples include: captopril, ramipril, enalapril, losartan potassium, bepridil and lisinopril. (12 Mar 1998) |
| aldose reductase inhibitor | <pharmacology> A class of drugs being studied as a way to prevent eye and nerve damage in people with diabetes. Aldose reductase is an enzyme that is normally present in the eye and in many other parts of the body. It helps change glucose (sugar) into a sugar alcohol called sorbitol. Too much sorbitol trapped in eye and nerve cells can damage these cells, leading to retinopathy and neuropathy. Drugs that prevent or slow (inhibit) the action of aldose reductase are being studied as a way to prevent or delay these complications of diabetes. (09 Oct 1997) |
| angiotensin-converting enzyme inhibitor | <pharmacology> A class of drugs used in the treatment of hypertension and heart failure. They exert their haemodynamic effect mainly by inhibiting the renin-angiotensin system and produce a reduction of peripheral arterial resistance. They also modulate sympathetic nervous system activity and increase prostaglandin synthesis. They cause mainly vasodilation and mild natriuresis without affecting heart rate and contractility. (14 Aug 2000) |
| aromatase inhibitor | Drugs, such as aminoglutethimide, that inhibit aromatase, an enzyme used in the synthesis of oestrogens. (05 Mar 2000) |
| beta-lactamase inhibitor | <pharmacology> Drugs such as clavulanic acid, which are used to inhibit bacterial beta-lactamases; often used with a penicillin or cephalosporin to overcome drug resistance. (05 Mar 2000) |
| Bowman-Birk inhibitor | A polypeptide that will inhibit both trypsin and chymotrypsin. (05 Mar 2000) |
| C1 esterase inhibitor | An a2-neuraminoglycoprotein that inhibits the enzymatic activity of C1 esterase, the activated first component of complement. A deficiency of this inhibitor results in a lack of inhibition of C1r and C1s leading to uncontrolled activation of the complement cascade and oedema. (05 Mar 2000) |
| carbonate dehydratase inhibitor | An agent, usually chemically related to the sulfonamides, that inhibits the activity of carbonate dehydratase, producing a general decrease in the formation of H2CO3 in the tissues. See: acetazolamide, dichlorphenamide. Synonym: carbonic anhydrase inhibitor. (05 Mar 2000) |
| carbonic acid inhibitor | <pharmacology> A group of diuretic medications which act to inhibit the enzyme carbonic anhydrase to create a metabolic acidosis. Many of these medications are used in the treatment of glaucoma. (27 Sep 1997) |
| carbonic anhydrase inhibitor | <pharmacology> A group of medications (sulphonamide drugs) which inhibit the enzyme carbonic anhydrase. These medications are used in the treatment of glaucoma. Examples include acetazolamide, dichlorphenamide and methazolamide. (27 Sep 1997) |
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|